NasdaqGS:INVAPharmaceuticals
Innoviva’s 2025 Earnings and NUZOLVENCE Launch Might Change The Case For Investing In Innoviva (INVA)
Innoviva, Inc. recently reported fourth-quarter 2025 revenue of US$114.61 million and net income of US$164.15 million, capping a full year in which revenue reached US$411.33 million and net income climbed to US$271.17 million.
These results highlight the growing weight of the Innoviva Specialty Therapeutics platform in the business, alongside the U.S. FDA approval of NUZOLVENCE®, which together reinforce the company’s shift from a royalty-focused model toward a broader commercial portfolio...